Pharma & Biotech - Page 24

Gilead Sciences (GILD) has prevailed in a long-running legal battle after the California Supreme Court ruled in the company’s favour over its tenofovir-based HIV treatments. The decision brings years of complex litigation

Sandoz, the generics and biosimilars spinout of Novartis, has struck a pair of settlement agreements to resolve long-running antitrust litigation brought by US state and federal enforcers. The company announced it had

Amgen has disclosed a significant cybersecurity breach in which hackers stole sensitive patient health information and proprietary company data from its cloud systems. The California-based drugmaker identified unauthorised activity within cloud storage

Curium has agreed to acquire all outstanding shares of Lantheus Holdings (LNTH) in a transaction that could be worth as much as $8 billion. Under the terms of the deal, Lantheus shareholders

Otsuka has reported positive full results from its Phase 3 VISIONARY trial, showing its drug Voyxact stabilised kidney function in adults with IgA nephropathy over two years. Voyxact, known clinically as sibeprenlimab-szsi,

The pharmaceutical industry has reached a pivotal moment at the midpoint of 2026, shaped by an accelerating dealmaking environment and rapidly shifting patient access dynamics. A widening gap in patient affordability is

Supernus Pharmaceuticals and Indivior Pharmaceuticals have agreed to merge in an all-stock transaction creating a major central nervous system biopharmaceutical company. The combined entity will generate approximately $2.2 billion in annual revenue,

The Section 232 pharmaceutical tariff regime is no longer a looming threat for the industry — it is now active law following the July 31, 2026, deadline. President Trump’s April 2, 2026,

A potential merger between AstraZeneca and Bristol Myers Squibb has been circulating on Wall Street, and the numbers involved are staggering. The Financial Times reported that the two pharmaceutical giants have held

Sanofi’s new chief executive Belén Garijo has spoken publicly for the first time about her plans to turn around the French pharmaceutical giant’s recent run of clinical disappointments. Garijo outlined a strategic